Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

PURPOSE: In hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+ HER2− MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combination with endocrine treatment. This study aims to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Hyehyun, Jeong, Jae Ho, Kim, Jeong Eun, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016296/
https://www.ncbi.nlm.nih.gov/pubmed/34176251
http://dx.doi.org/10.4143/crt.2021.205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016296/
https://www.ncbi.nlm.nih.gov/pubmed/34176251
http://dx.doi.org/10.4143/crt.2021.205

Ejemplares similares